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Introduction
Atopic dermatitis (AD) is an inflammatory skin disorder with chronic, relapsing, pruritic, inflammatory 
eczematous eruption that usually develops in early childhood (1). The pathogenesis of  AD is a complex 
interplay of  genetic, environmental, skin barrier (including microbiota), and immunological factors (2), 
which mainly contribute to the development and progression of  AD. Both innate and adaptive immune 
cells are involved in the complex immune network in cutaneous inflammation, yet CD4+ T cells are known 
to be a key population promoting AD pathogenesis (3, 4). Among the Th subsets, Th2 cells are the key 
pathogenic mediators of  AD progression by producing IL-4, IL-5, IL-10, IL-13, and IL-31, which enhance 
IgE levels and development and survival of  eosinophils (5). Th17 and Th22 immune responses are also 
reported in skin-related inflammatory diseases, including AD. Among different kinds of  skin cells, kerat-
inocytes play an important function in the regulation of  inflammation, responding to environmental and 
proinflammatory stimuli such as the cytokines IL-17 and IL-22 released by Th17 or Th22 cells (6–11). 
However, the mechanisms occurring via the activity of  cytokines such as IL-17 and IL-22 from pathogenic 
Th cells under conditions of  AD are not fully understood.
Expression array technologies have identified a set of  genes, including those encoding cytokines, 
chemokines, IgE receptor, proteases, and pattern recognition receptors (PRRs), that are relevant to AD 
pathogenesis (12). Recent genome-wide association studies (GWAS) have also updated the landscape of  
AD genetics, and for the most part, gene sets were related to immune signaling and T cell polarization (13). 
Atopic dermatitis (AD) is a complex inflammatory skin disease mediated by immune cells of 
both adaptive and innate types. Among them, CD4+ Th cells are one of major players of AD 
pathogenesis. Although the pathogenic role of Th2 cells has been well characterized, Th17/Th22 
cells are also implicated in the pathogenesis of AD. However, the molecular mechanisms underlying 
pathogenic immune responses in AD remain unclear. We sought to investigate how the defect in 
the AD susceptibility gene, Ets1, is involved in AD pathogenesis in human and mice and its clinical 
relevance in disease severity by identifying Ets1 target genes and binding partners. Consistent with 
the decrease in ETS1 levels in severe AD patients and the experimental AD-like skin inflammation 
model, T cell–specific Ets1-deficient mice (Ets1ΔdLck) developed severe AD-like symptoms with 
increased pathogenic Th cell responses. A T cell–intrinsic increase of gp130 expression upon 
Ets1 deficiency promotes the gp130-mediated IL-6 signaling pathway, thereby leading to the 
development of severe AD-like symptoms. Functional blocking of gp130 by selective inhibitor 
SC144 ameliorated the disease pathogenesis by reducing pathogenic Th cell responses. Our results 
reveal a protective role of Ets1 in restricting pathogenic Th cell responses and suggest a potential 
therapeutic target for AD treatment.
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While not detracting from the importance of  maintaining the skin barrier in the prevention and treatment 
of  AD, the above findings led to new therapeutic approaches targeting immune modulation of  AD. Recent-
ly, GWAS have identified 11 new loci for AD using a large number of  cohorts (13). Among them, Ets1 was 
selected with the highest P value and further supported association with self-reported allergy (14). Howev-
er, the method by which defective Ets1 leads to AD development is still unclear.
Ets1 is prototype of  Ets family transcription factors, specifically binding to core GGAA/T element, 
and is shown to have versatile roles in various biological processes by regulating expression of  multifarious 
target genes (15). Although expression of  Ets1 is ubiquitous, high levels of  Ets1 expression is strictly con-
fined to the lymphoid organ (16, 17), indicating crucial roles of  Ets1 for the development and functionality 
of  lymphoid cells. Consistently, germline Ets1-KO mice (Ets1–/–) showed impaired development of  NK, 
NKT, and Treg cells (18–21) and incomplete thymocyte development (22, 23), suggesting crucial roles 
of  Ets1 in hematopoietic development. In T cells, Ets1 modulates various T cell–specific genes such as 
Tcra and Tcrb (24). Additionally, Ets1 has been shown to act as a positive regulator for Th1 differentiation 
(25) or a negative regulator for Th17 differentiation (26), suggesting that Ets1 mainly modulates effector 
function of  Th cells. Although the various studies have shown crucial roles of  Ets1 in the immune system, 
pathophysiological roles of  Ets1 in CD4+ T cells are still under scrutiny in a variety of  immune disorders.
In this study, we have examined the role of  Ets1 in AD development and progression. We show that 
absence of  Ets1 triggered spontaneous development of  AD-like symptoms, and T cell–specific Ets1-deleted 
mice (Ets1ΔdLck) were more susceptible to experimental AD-like skin inflammation. In T cells, Ets1 directly 
regulates pathogenicity of  CD4+ T cells by acting as a strong transcriptional repressor of  multiple targets 
involved in AD development. Our results demonstrate an importance role of  Ets1 as a key regulator in the 
development and progression of  AD.
Results
Inverse correlation between Ets1 expression and pathogenesis of  AD. In order to investigate the clinical relevance 
of  Ets1 expression in AD pathogenesis, we first analyzed the expression level of  ETS1 in skin residual 
lymphocyte from AD patients with varying disease severity (Figure 1A and  Supplemental Figure 1; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.124202DS1). In weak 
and moderate AD patients diagnosed by their clinical symptoms, approximately 60% of  tissue-infiltrated 
lymphocytes were shown to express ETS1 (weak, 444 ETS1+ cells among 721 cells; moderate, 1,400 ETS1+ 
cells among 2,271 cells). However, in the case of  severe AD patients, ETS1 expression in tissue-infiltrated 
lymphocytes was significantly reduced to 20% (2,137 ETS1+ cells among 10,209 cells) (Figure 1, A and B) 
suggesting that reduced ETS1 level is highly correlated with severe AD. To corroborate these findings in 
mice, we analyzed Ets1 level in an experimental AD-like skin inflammation model induced by alternative 
application of  hapten and house dust mite (HDM) extract in BALB/c mice (27) (Supplemental Figure 2A). 
Upon induction of  the disease, mice showed clinical and molecular facets of  AD-like symptoms, including 
destruction of  ear tissues (Supplemental Figure 2B), increased ear thickness (Supplemental Figure 2C), 
elevated total and antigen-specific IgE (Supplemental Figure 2, D and E), and altered skin barrier integrity 
(Supplemental Figure 2F). Ets1 expression was decreased in lymphocytes (CD4+ T cells and CD19+ B cells) 
from the skin-draining lymph nodes (dLNs) upon induction of  AD-like skin inflammation (Figure 1C), 
substantiating the notion that reduced Ets1 level is highly correlated with severe AD-like inflammation. In 
addition, we found that Ets1 germline–KO mice (Ets1–/– in C57BL/6 genetic background) bred under con-
ventional conditions developed AD-like pruritic and erosive skin inflammation (Figure 1D). The incidence 
of  AD-like skin inflammation was around 40% in Ets1-deficient mice (Figure 1E), with enhanced serum 
IgE and IgG levels (Figure 1, F and G). Collectively, these data suggest the role of  Ets1 as a protective reg-
ulator of  AD pathogenesis.
Ets1 deficiency increases the susceptibility to experimental AD. We also confirmed that Ets1–/– mice are more 
susceptible to induction of  AD-like skin inflammation in specific pathogen free (SPF) conditions. Com-
pared with littermate control (LMC), Ets1–/– mice showed significantly increased ear thickness and clinical 
symptoms, including edema, erosion, erythema, and heavy infiltration of  mononuclear cells (Figure 2, A 
and B). Moreover, Ets1–/– mice showed much higher level of  total serum IgE (Figure 2C), HDM-specific 
IgE (Figure 2D), and total serum IgG (Figure 2E). Consistent with histopathology shown in Figure 2A, sig-
nificantly increased infiltration of  immune cells such as CD4+ T cells and CD19+ B cells were observed in 
inflamed tissue of  Ets1–/– mice (Supplemental Figure 3, A–C), leading to an alteration in expression levels 
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of  skin-barrier integrity–related molecules (Figure 2F). Ets1–/– mice showed much lower levels in filaggrin, 
claudin, loricrin, S100A8, and S100A9 compared with LMC mice. These data suggest that deficiency of  Ets1 
makes mice more susceptible for the development of  AD-like symptoms, implying the vigilant roles of  Ets1 
in AD pathogenesis.
T cell–specific Ets1 deletion enhances the susceptibility to AD induction. Next, we tested whether CD4+ 
T cells are involved in AD pathogenesis. Since systemic deletion of  Ets1 leads to profound immune 
cell dysregulation (18–21, 25, 26), including defective T cell development (Supplemental Figure 4), we 
decided to delete Ets1 expression in mature CD4+ T cells. We generated Ets1 floxed mice (Ets1fl/fl) that 
have the exon 7 DNA binding regions flanked by 2 loxp sites (28). Ets1fl/fl mice were crossed with distal 
Lck-Cre mice, not with CD4-Cre mice, to avoid a developmental defect of  T cell due to deletion of  
Ets1 in the thymus (28, 29). Indeed, distal Lck-Cre Ets1fl/fl mice (Ets1ΔdLck) showed specific deletion of  
Ets1 in peripheral CD4+ T cells (Supplemental Figure 5A). Ets1ΔdLck mice showed no defect in thymic 
T cell development (Supplemental Figure 5B) and thymic Treg development (Supplemental Figure 5C), 
and they showed normal peripheral CD4+ T cells proportion (Supplemental Figure 5, D and E) and 
overall intact cellularity in lymphoid tissues (Supplemental Figure 5F). In contrast to germline Ets1–/– 
mice, Ets1ΔdLck mice did not show any signs of  autoimmune diseases. Next, we tested whether Ets1ΔdLck 
mice are susceptible to induction of  AD-like skin inflammation compared with LMC mice. Indeed, 
Ets1ΔdLck mice were more susceptible to the disease induction and showed AD-like pathophysiology 
similar to germline Ets1–/– mice, including increased ear thickness (Figure 3, A and B), serum total IgE, 
antigen-specific IgE and IgG levels (Figure 3, C–E), and massive mononuclear cells inflation (Supple-
mental Figure 6A), and they showed an alteration in expression levels of  skin-barrier integrity–related 
molecules (Supplemental Figure 6B). dLN CD4+ T cells isolated from Ets1ΔdLck mice at the peak of  the 
disease showed a massive increase in cellularity (Supplemental Figure 6C) and an increase in the levels 
of  Th2 cytokines (IL-4, IL-10, and IL-13) (Supplemental Figure 6D). Moreover, we also observed sig-
nificant elevation of  IL-17A and IL-22, but not IFN-γ, production in Ets1ΔdLck mice (Figure 3F). We also 
tested whether enhanced AD-like skin inflammation in Ets1ΔdLck mice is due to an alteration of  Tregs 
under homeostatic and disease conditions. No significant differences were observed in Treg frequency 
in homeostatic conditions between the LMC and Ets1ΔdLck mice (Supplemental Figure 5, C and D). 
Ets1ΔdLck mice also did not show any defect in Treg frequency, even in AD-like disease conditions (Sup-
plemental Figure 7A). We also analyzed frequency of  Helios+ (Supplemental Figure 7B) and Ki-67+ 
(Supplemental Figure 7C) among CD4+Foxp3+ Tregs, as they are functional markers of  suppressive 
activity of  Tregs (30, 31). No significant differences were observed between LMC and Ets1ΔdLck mice 
under disease conditions. To further confirm that the causality of  Ets1-dependent intrinsic defects in 
CD4+ T cells is the key mechanism for AD pathogenesis in vivo, we performed adoptive transfer exper-
iments. CD45.2+CD4+ T cells from LMC or Ets1ΔdLck mice, together with WT B cells (CD45.1+), were 
adoptively transferred into Rag1–/– mice; then, the mice were induced to develop experimental AD-like 
skin inflammation by alternative application of  hapten and HDM extract. The recipient mice reconsti-
tuted with Ets1ΔdLck CD4+ T cells developed severe AD-like symptoms, such as severe tissue destruction 
(Figure 3G), increased ear thickness (Figure 3H), and higher levels of  IgE (Figure 3, I and J). Further-
more, recipient mice reconstituted with CD4+ T cells from Ets1ΔdLck mice showed significantly higher 
frequencies of  IL-17A+ and IL-22+ populations than the recipient mice reconstituted with LMC CD4+ 
T cells (Figure 3K). These results collectively suggest that Ets1 in CD4+ T cells has an intrinsic role to 
inhibit the differentiation of  IL-17A/IL-22–producing pathogenic Th cells in the context of  AD patho-
genesis.
Ets1 deficiency enhances pathogenic Th cell response in AD development. To identify the molecular mech-
anisms responsible for enhanced AD-like pathogenesis upon Ets1 deficiency in CD4+ T cells, we com-
pared transcriptome profile between CD4+ T cells from LMC and Ets1ΔdLck mice at the peak of  disease 
progression by performing RNA sequencing (RNA-seq). Among the genes expressed in the CD4+ T cells 
(~13,113), 1,526 genes were upregulated and 626 genes were downregulated in Ets1-deficient CD4+ T cells 
(defined as genes with at least 1.5-fold change, adjusted P ≤ 0.05, and expression above a minimal threshold 
based on the distribution of  all expressed genes) relative to their expression in LMC CD4+ T cells (Figure 
4A). Various inflammatory pathways such as inflammatory responses (in Gene Ontology [GO] terms) 
(http://geneontology.org) and cytokine-to-cytokine receptor interaction (in Kyoto Encyclopedia of  Genes 
and Genomes [KEGG] pathways) (https://www.genome.jp/kegg/) were significantly enriched in Ets1-de-
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Figure 1. Ets1 expression is significantly reduced in skin lesion of severe AD patients and experimental animal model. (A) H&E staining of the 
human skin biopsies confirmed the clinical diagnoses of weak, moderate, and severe atopic dermatitis (AD). Ets1+ lymphocytes were analyzed by IHC 
in the same tissues. (B) Frequency of Ets1+ lymphocytes from AD patient group with different disease severity is summarized in the graph. The data 
are expressed as mean ± SEM. ****P ≤ 0.0001; 1-way ANOVA. (C) After 4 weeks of AD induction in BALB/c mice, expression level of Ets1 was analyzed 
in peripheral CD4+ T and CD19+ B cells from skin-draining LNs by qPCR or immunoblotting. Quantification represents 3 independent experiments. (D) 
Representative phenotype of spontaneous AD-like skin inflammation developed in Ets1–/– mice (in C57BL/6 genetic background) under conventional 
conditions. (E) Incidence of AD-like skin inflammation among age-matched littermate controls (LMC) and Ets1–/– mice was calculated (n = 43 of LMC 
and 21 of Ets1–/– mice). (F and G) The total IgE and IgG levels in serum from mice groups at 12–16 weeks kept in conventional conditions were measured 
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ficient CD4+ T cells (Table 1). Interestingly, genes related with pathogenic Th17 immune response (Il17a/f, 
Il22, Rora, and Rorc) were significantly upregulated in Ets1-deficient CD4+ T cells, together with some of  
the Th2-related genes (Il4, Il10, and Ccr8) (Figure 4B). Next, we tested whether Ets1 deficiency leads to 
dysregulation of  Th cell differentiation in non-AD conditions. Naive CD4+ T cells isolated from LMC or 
Ets1ΔdLck mice were differentiated into Th1, Th2, Th17, or pathogenic Th17 cells in vitro (32); then, levels 
of  cytokines were analyzed. In line with a previous report in germline Ets1–/– mice (25), CD4+ T cells from 
the Ets1ΔdLck mice showed reduced IFN-γ production but similar T-bet expression under in vitro Th1 differ-
entiation conditions (Supplemental Figure 8A). Likewise in germline Ets1–/– mice (26), CD4+ T cells from 
the Ets1ΔdLck mice showed increased IL-17A production under in vitro Th17 differentiation (Supplemental 
Figure 8B). Ets1-deficient T cells from Ets1ΔdLck mice showed a similar frequency of  IL-4–producing Th2 
cells with comparable GATA-3 expression (Figure 4C). Interestingly, although we could still detect com-
parable expression of  RORγt and AHR, a significant increase in IL-17 and IL-22 production was observed 
in the Ets1-deficient CD4+ T cells under pathogenic Th17 differentiation conditions (Figure 4D). Ex vivo 
CD4+ T cells from Ets1ΔdLck mice also showed significantly enhanced production of  IL-17A and IL-22 (Sup-
plemental Figure 8, C–E). No significant differences were observed in Th2-related cytokines (Supplemental 
Figure 8, C–E). These results suggest that Ets1 deficiency may enhance pathogenic Th17 (IL-17A and 
IL-22) production, which mediates AD-like skin inflammation.
Elevated gp130 mediates pathogenic Th17 cell differentiation in Ets1-deficient T cells. Since Ets1-deficient 
CD4+ T cells did not show a significant alteration in key regulators of  Th17 such as RORγt and AHR 
under ex vivo and in vitro differentiation, we hypothesized that upstream signaling molecules involved 
in differentiation of  Th17 cells might be affected in Ets1-deficient CD4+ T cells. Indeed, among various 
pathogenic Th17 genes analyzed in the disease condition, we identified Il6st (encodes gp130, a signaling 
subunit for the IL-6 receptor complex) as a key target gene (Figure 4B). Il6st showed a significant eleva-
tion in Ets1-deficient CD4+ T cells, while Il6ra level was not altered (Figure 5, A and B) under homeo-
static conditions. To further confirm the intrinsic role of  Ets1 in regulation of  gp130, a mixed BM chi-
mera experiment was performed. BM cells from LMC (CD45.2 Ets1fl/fl) or Ets1-deficient mice (CD45.2 
Ets1ΔdLck) were mixed with BM cells from congenic CD45.1 WT mice at a 1:1 ratio and injected into sub-
lethally irradiated Rag1–/– mice. Indeed, we could clearly observe increased gp130 levels in the Ets1-defi-
cient BM transferred group, implying that Ets1 has a cell-intrinsic role as a transcriptional repressor for 
gp130 expression (Supplemental Figure 9A). To further dissect molecular mechanisms of  Ets1 mediated 
Il6st expression, we reanalyzed previously reported Ets1 ChIP-seq data using ex vivo CD4+ T cells from 
the WT mice (33, 34). Indeed, we could observe a significant enrichment of  Ets1 to the promoter region 
of  Il6st and upstream regulatory elements, as well (Figure 5C). We also analyzed histone modifications 
status in the promoter region of  Il6st (e.g, histone H3 Lys 27 acetylation, H3K27ac) as a parameter for 
the permissive chromatin state (35). ChIP-PCR analysis was performed with anti-H3K27ac antibody on 
the CD4+ T cells isolated from LMC and Ets1ΔdLck mice. Indeed, we found an increased enrichment of  
H3K27ac in the promoter region of  Il6st (Figure 5D) in Ets1-deficient CD4+ T cells. Rpl30 and Mest 
were used as positive and negative controls, respectively. We also analyzed the levels of  phospho-STAT3, 
which is the key factor as a downstream signal involved in gp130-mediated trans-signaling pathways for 
Th17 response (36, 37). Indeed, Ets1-deficient CD4+ T cells showed stronger phosphorylation of  STAT3 
(Figure 5E) upon IL-6/sIL-6R complex stimulation and showed higher IL-17A and IL-22 levels, even at 
limited doses of  IL-6 (Figure 5F). These results enlightened the role of  Ets1 as the transcriptional repres-
sor for Il6st expression to inhibit hyperactivation of  the STAT3-mediated pathogenic Th17 response.
Administration of  gp130 inhibitor suppresses AD pathogenesis of  Ets1ΔdLck mice. To further validate the 
functional importance of  gp130, we determined the effect of  gp130 inhibition on AD-like pathogenesis 
of  Ets1ΔdLck mice. For this purpose, we employed SC144 as a specific inhibitor of  gp130. SC144 has been 
known to induce gp130 phosphorylation (S782) and deglycosylation to reduce STAT3 phosphorylation 
and its nuclear translocation, which subsequently inhibits the expression of  downstream target genes 
(38). Administration of  mock (vehicle) or SC144 was initiated a week after AD-like disease induction 
by ELISA (data comes from the analysis of 7 individual mice in each group). Error bars represent the mean ± SEM. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 
0.0005; ****P ≤ 0.0001; Student’s t test. 
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and continued every day (weekdays) by i.p. injection until the end of  experiment. Compared with the 
vehicle-treated group, SC144 treatment significantly inhibited the AD-like symptoms in Ets1ΔdLck mice, 
characterized by reduced pathophysiology and ear thickness (Figure 6, A and B). This was associated 
with reduced lymphocytes infiltration (Figure 6, C and D) and reduced serum IgE (Figure 6, E and F) 
and IgG level (Figure 6G). Moreover, SC144 treatment significantly reduced IL-17A and IL-22 produc-
tion in CD4+ T cells from the dLNs compared with vehicle controls (Figure 6H). These results indicate 
the causal function of  gp130 in Ets1ΔdLck CD4+ T cells for the exaggerated AD-like pathology, and they 
are suggestive of  a potential therapeutic remedy for AD upon gp130 blockade.
Discussion
In this study, we revealed an important role of  Ets1 as the key transcriptional repressor to preclude the 
Figure 2. Ets1 deficiency promotes experimental AD pathogenesis under SPF conditions. (A) Representative photographs of mouse ears from each group 
(upper) and H&E staining of the ear biopsies (lower) confirmed clinical symptoms of AD. (B) Ear thickness during the course of AD was measured 24 hours 
after DNCB or HDM extract application by using a dial thickness gauge. The data are expressed as mean ± SD. ****P ≤ 0.0001 (from day 17–31); 2-way 
ANOVA. (C–E) Total IgE (C), HDM allergen-specific IgE (D), and total IgG levels (E) in serum from the mouse groups were measured by ELISA. (F) RNA was 
collected from the cells of ear tissues, and the relative levels of filaggrin, claudin, loricrin, S100A8, and S100A9 were evaluated by qPCR after normaliza-
tion with Hprt level. Data represent results from 3 independent experiments. Error bars represent the mean ± SEM. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.0005; 
****P ≤ 0.0001; Student’s t test.
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Figure 3. Specific deletion of Ets1 in mature T cells (Ets1ΔdLck) promotes AD pathogenesis by enhancing Th17 and Th2 responses. (A) Representa-
tive photographs of mouse ears from each group (upper) and H&E staining of the ear biopsies (lower) confirmed the clinical symptoms of AD. (B) 
Ear thickness during the course of AD was measured. The data are expressed as mean ± SD. ****P ≤ 0.0001 (from day 17–31); 2-way ANOVA. (C–E) 
Total IgE (C), HDM allergen-specific IgE (D), and total IgG levels (E) in serum from the mouse groups were measured by ELISA. (F) Ex vivo isolated 
total lymphocytes from skin-draining LNs under AD were given PMA and ionomycin stimulation with GolgiStop or GolgiPlug for 4 hours. Intracellu-
lar staining of IL-17, IL-22, and IFN-γ by CD4-gated T cells were analyzed. (G) Naive CD4+ T cells were isolated from LMC and Ets1ΔdLck mice by means 
of fluorescence-activated cell sorting and transferred i.v. into Rag1−/− mice (5 × 105/mouse) with WT CD45.1+CD19+ B cells (2 × 106/mouse). AD was 
induced the day after cell transfer. H&E staining of the ear biopsies confirmed clinical symptoms of AD. (H) Ear thickness during the course of AD was 
measured. The data are expressed as mean ± SD. **P ≤ 0.005; ***P ≤ 0.0005; ****P ≤ 0.0001 (from day 17–24); 2-way ANOVA. (I and J) The total IgE 
(J) and HDM allergen-specific IgE levels (J) in serum from the mouse groups were measured by ELISA. (K) Intracellular staining of IL-17 and IL-22 by 
CD4-gated T cells were analyzed. Data represent results from 3–4 independent experiments. Error bars represent the mean ± SEM. *P ≤ 0.05; ****P ≤ 
0.0001; Student’s t test.
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differentiation of  pathogenic Th17 cells, thereby suppressing the development and progression of  AD-like 
skin inflammation. Furthermore, we identified Il6st (gp130) as the key factor involved in exaggerated 
AD-like pathology in the absence of  Ets1 expression.
Previously, Ets1 has shown its causal roles in various inflammatory diseases. Various GWAS have 
identified ETS1 as candidate factor responsible for the susceptibility to various human autoimmune diseas-
es (39–45), including systemic lupus erythematosus (SLE) (46). Intriguingly, a recent study has identified 
11 new genetic loci associated with AD susceptibility that includes ETS1 with the highest P value (13). In 
this study, we defined an important role of  Ets1 in AD pathogenesis. We could observe a strong negative 
correlation of  ETS1 expression in lymphocytes with disease severity among AD patients and spontaneous 
AD-like skin inflammation in germline Ets1–/– mice. Because of  versatile roles of  Ets1 in various cell types 
such as survival of  T cells (47), keratinocyte differentiation (48), and ILC2 development (49), it was hard 
to decipher which types of  cells are mainly responsible for development of  AD-like skin inflammation in 
the germline Ets1–/– system. To overcome this issue, we generated Ets1ΔdLck mice (details described below) 
Figure 4. RNA-seq analysis of CD4+ T cells from LMC and Ets1ΔdLck mice under AD condition. RNA was collected from FACS-sorted cells of skin-drain-
ing LNs at the peak of the disease onset (day 31). (A) Plot of gene expression (as log2 normalized read count) in LMC vs. Ets1ΔdLck-derived CD4+ T cells. 
Significantly down- and upregulated genes (defined as genes with at least 1.5-fold change, adjusted P ≤ 0.05, and expression above a minimal threshold 
based on the distribution of all expressed genes) are colored blue or red, respectively, and their numbers are shown. (B) Heatmap of selected genes were 
depicted. Three replicates are shown in order. (C and D) Naive CD4+ T cells from LMC and Ets1ΔdLck mice were cultured 3–4 days with plate-bound anti-CD3 
and anti-CD28 in the presence of skewing cytokines IL-4 and anti–IL-12 for Th2 and IL-1β and IL-6 and IL-23 for pathogenic Th17. Expression of the indicated 
cytokines and transcription factors were analyzed by flow cytometry. Representative plot comes from the analysis of 4–6 individual mice.
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to study the T cell–specific role of  Ets1 in AD pathophysiology. Even though we could not find any immu-
nological abnormality, such as naive/memory T cell ratio and Treg frequency, Ets1ΔdLck mice recapitulated 
overall AD-like symptoms comparable with the symptom of  germline Ets1–/– mice, indicating that T cells 
are the causal population to induce AD pathogenesis in the absence of  Ets1. Our study provides cellular 
details how the dysfunction of  the transcriptional regulator Ets1 promotes pathogenic Th cell responses 
leading to AD pathogenesis.
Though a previous study has suggested the negative function of  Ets1 in Th17 differentiation (26), the 
molecular action mechanisms of  Ets1 for Th17 differentiation and pathophysiological evidence remain elu-
sive. How does the deficiency of  Ets1 in CD4+ T cells trigger AD pathogenesis? Multiple mechanisms might 
be involved, including the enhanced population of  IL-17A– and IL-22–producing Th cells and gp130-medi-
ated trans-signaling pathways for AD pathogenesis (36). CD4+ T cells from Ets1ΔdLck mice under AD-like skin 
inflammation highly produced pathogenic Th cell response–related cytokines, including IL-17A and IL-22 
(Figure 3, F and K). An increased Il6st (gp130) level might be the key step in this procedure (Figure 5, A and 
B, and Supplemental Figure 9A). gp130 has been known as the key upstream component of  Th17 cell signal-
ing through functional enhancement of  STAT3 activity (Figure 5E) (37), and it may serve as a key mediator 
of  pathogenic Th17 cell response–related gene expression (50) in Ets1ΔdLck mice under AD-like skin inflamma-
tion conditions. Ets1 may also contribute to the progression of  autoimmunity by controlling the expression 
of  gp130 in IL-6–mediated signaling (36, 51). In addition, Ets1 may also regulate Th17 differentiation by 
orchestrating inhibitory (Il2 expression through Aiolos) (52) and facilitative (IL-6 signaling sensitivity through 
its receptor expression) mechanisms. Indeed, Ets1 deficiency in CD4+ T cells enhanced the expression of  
Ikzf3 (Aiolos), a known repressor for IL-2 expression in T cells (52) (Supplemental Figure 9, B–D), through 
direct binding in the Ikzf3 locus (Supplemental Figure 9E), thereby reducing IL-2 expression (Supplemental 
Figure 9F). In addition to CD4+ T cells, Ets1 may also regulate the expression levels of  molecules related with 
skin barrier integrity. Compared with LMC mice, exaggerated skin inflammation was observed in Ets1ΔdLck 
mice (Supplemental Figure 6B). Skin lesions from Ets1ΔdLck mice showed significantly altered gene expression 
levels, including Flg2, Cldn1, and Lor and antimicrobial proteins S100A8/A9, a known target of  IL-17A and 
IL-22 (53, 54). Taking one more step forward from these cellular mechanisms, we endeavored to uncover the 
molecular functions of  Ets1 in CD4+ T cells. It has been shown that Ets family transcription factors mainly act 
as coactivators (55), but our data also suggest a dominant role of  Ets1 as the transcriptional corepressor (Fig-
ure 4B; Figure 5, A and B; and Supplemental Figure 9, B and C). Our unbiased interactome analysis of  Ets1 
by IP/liquid chromatography/tandem mass spectrometry revealed that Ets1 may form a corepressor complex 
through interaction with HDAC1, mSin3a, HCFC1, and Suds3 (56–58) (Supplemental Figure 10). Moreover, 
we confirmed increased Il6st in Ets1-deficient CD4+ T cells accompanied by epigenetic modification (Figure 
5D). Ets1 may act as a molecular switch by cooperating with the Sin3A repressor complex to prevent patho-
genic Th cell differentiation and AD pathogenesis in CD4+ T cells.
While our study substantially advances the current understanding of  AD pathogenesis, several ques-
tions remain. Correlation analysis between ETS1 levels and disease, upon analyzing ETS1 levels in CLA+ 
Table 1. Functionally enriched Gene Ontology (GO) categories and KEGG pathways of the upregulated 
DEGs were analyzed by DAVID tool
GO term P value
Immune system process (GO:0002376) 3.42 × 10–28
Immune response (GO:0006955) 2.5 × 10–18
Cell cycle (GO:0007049) 5.34 × 10–16
Inflammatory response (GO:0006954) 8.29 × 10–16
KEGG pathway term P value
IBD 7.61 × 10–11
Cytokine-cytokine receptor interaction 5.58 × 10–10
Transcriptional misregulation in cancer 8.07 × 10–8
Intestinal immune network for IgA production 1.93 × 10–7
IBD, inflammatory bowel disease.
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Figure 5. Effect of Ets1 deficiency on gp130 expression, IL-17A and IL-22 produc-
tion, and IL-6–mediated STAT3 activation. (A) RNA was collected from the naive 
CD4+ T cells from LMC and Ets1ΔdLck mice, and relative expression of Il6st and 
Il6ra were evaluated by qPCR (n = 3). (B) Protein levels of Il6st (gp130) and Il6ra 
(IL-6Rα) were examined by surface staining. Mean fluorescence intensity (MFI) 
is presented (n = 4). (C) Ets1 ChIP-seq confirmed binding of Ets1 on regulatory 
elements of Il6st locus. Numbers represent 2 different sets of data. (D) Histone 
modification (H3K27ac) of Il6st locus was analyzed by ChIP-qPCR. Quantification 
represents 3 independent experiments. (E) Naive CD4+ T cells from LMC and 
Ets1ΔdLck mice were stimulated with IL-6/sIL-6R complex for the indicated times, 
and STAT3, phospho-STAT3, and actin expression was examined by immuno-
blotting. The blots were scanned, and the levels of p-STAT3 were normalized to 
the total amount of STAT3 and depicted as a graph. (F) Naive CD4+ T cells from 
LMC and Ets1ΔdLck mice were cultured 3–4 days with plate-bound anti-CD3 and 
anti-CD28 in the presence of skewing cytokines IL-1β, IL-6, and IL-23. IL-6 was 
given under optimal (20 ng/ml) or limited (2 ng/ml) conditions. Expressions of 
the indicated cytokines were analyzed by flow cytometry. Representative plot 
comes from the analysis of 4–6 individual mice. Error bars represent the mean ± 
SEM. **P ≤ 0.005; ***P ≤ 0.0005; ****P ≤ 0.0001; Student’s t test.
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Figure 6. The gp130 inhibitor SC144 suppresses pathophysiology of AD in Ets1ΔdLck mice. Experimental AD was induced in LMC and Ets1ΔdLck mice. 
The gp130 inhibitor, SC144, was administered via i.p. routes a week after the initial sensitization (5 times during weekdays for 3 weeks) and contin-
ued until the end of experiment. (A) H&E staining of the ear biopsies confirmed the clinical symptoms of AD. (B) Ear thickness during the course of 
AD was measured. The data are expressed as mean ± SD. ****P ≤ 0.0001 (from day 21–31); 2-way ANOVA. (C and D) Cells from the ear tissues were 
collected from each group of mice under AD (C) and absolute number and frequency of CD4+ T cells were calculated (D). (E–G) The total IgE (E), HDM 
allergen-specific IgE (F), and total IgG levels (G) in serum from the mouse groups were measured by ELISA. (H) Intracellular staining of IL-17 and 
IL-22 by CD4-gated T cells were analyzed. Data represent results from 3 independent experiments. Error bars represent the mean ± SEM. *P ≤ 0.05; 
**P ≤ 0.005; ***P ≤ 0.0005; ****P ≤ 0.0001; Student’s t test.
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memory CD4+ T cells in AD patients, may help in substantiating a direct link between ETS1 expression 
and AD pathogenesis. It will be also interesting to define whether Ets1 also plays an important role in 
regulation of  Th17-mediated inflammatory disorders, such as an infection model and skin psoriasis (59). 
Moreover, it will be interesting to test whether treatment with IL-17 or IL-17 receptor blocking antibody 
could ameliorate AD-like pathogenesis in Ets1ΔdLck mice and AD patients.
Our study suggests the role of  Ets1 as a key regulator of  pathogenic Th cell–mediated AD develop-
ment. Dysregulation of  Th17 cell response and gp130 in Ets1 deficiency may be causative to pathogenesis 
of  various autoimmune diseases. IL-17A– and IL-22–producing Th cells are major pathogenic regulators 
not only in skin inflammatory disease, but also in various autoimmune diseases. In this regard, modulation 
of  Ets1 activity or its target genes could be considered as potentially novel therapeutic targets for inflamma-
tory immune disorders, including AD and autoimmune diseases.
Methods
Mice. C57BL/6, CD45.1, distal-Lck (dLck)-cre, and Rag1–/– mice were originally obtained from The Jackson 
Laboratory. BALB/c mice were purchased from Orient Bio Inc. Ets1–/– mice carrying a germline dele-
tion of  Ets1 were previously described (25) and provided by I-Cheng Ho (Harvard Medical School, Bos-
ton, Massachusetts, USA). Ets1fl/fl mice were generated by Toolgen and Macrogen (Seoul, Korea). In brief, 
RNA-guided endonucleases (RGENs) mediating targeted genome modification was performed against the 
seventh exon of  Ets1, which contains part of  the DNA binding domain (28). T cell–specific conditional 
Ets1-KO mice (Ets1ΔdLck) were generated by breeding Ets1fl/fl mice to dLck-Cre mice. Mice were maintained 
in the animal facility of  POSTECH Biotech Center in SPF conditions. Mixtures of  male and female mice 
were used, matched between groups. Mice were sacrificed between the ages of  8–10 weeks.
Study subjects. Skin biopsy specimens were obtained after informed consent from all patients. All the 
patients (n = 22) were from outpatient clinics of  Chonnam National University Hospital (Gwangju, South 
Korea). Each subject was classified into 3 groups based on their clinical symptoms. A severity score was 
recorded for each of  the 4 regions of  the body. The severity score is the sum of  the intensity scores for 4 
signs. The 4 signs are redness, thickness, scratching, and lichenification. The average intensity of  each sign 
in each body region is assessed as none, mild, moderate, and severe.
Induction of  AD-like skin inflammation. Induction of  experimental AD-like skin inflammation was per-
formed by following a protocol described previously (27). Briefly, surfaces of  both ear lobes were stripped 
5 times with surgical tape (Medi-Korea). After stripping, 20 μl of  2% 2,4-dinitrochlorobenzene (DNCB, 
MilliporeSigma) dissolved in acetone/olive oil (1:3) solution was painted on each ear. After 4 days, 20μl 
of  10 mg/ml HDM extract (dermatophagoides farinae, GREER) dissolved in PBS containing 0.5% Tween 
20 was repainted. The DNCB/HDM treatment was repeated weekly for 4 weeks. SC144 treatment was 
performed via i.p. route at a concentration of  7 mg/kg/day. The treatment started the week after the first 
DNCB application and was repeated daily for another 4 days. After a 2-day pause, this 5 days–on and 2 
days–off  SC144 treatment protocol was repeated. Ear thickness was measured 24 hours after DNCB or 
HDM application by using a dial thickness gauge (Kori Seiki MFG Co.). The animals were sacrificed on 
day 31. Blood samples were collected by eye bleeding. Plasma was prepared from the blood samples and 
stored at –70°C for further analysis. After blood collection, the ears were removed and subjected to histo-
pathological analysis. For AD-like skin inflammation induction in Ets1-/-  mice, naive CD4+ T cells (5 × 
105 per mouse) from LMC and Ets1ΔdLck mice sorted by flow cytometry (MoFlo XDP and MoFlo Asterios, 
Beckman-Coulter) were i.v. transferred into Rag1−/− mice, together with WT CD45.1+ CD19+ B cells (2 × 
106 per mouse). One day later, the recipient mice were induced with experimental AD-like skin inflamma-
tion as described above. The AD-like disease incidence rate of  experimental AD induction with Ets1–/–, 
Ets1ΔdLck, and Rag1–/– adoptive transfer with Ets1-deficient CD4+ T cells showed more than 90%.
Histological analysis. Skin biopsies from the patients and ear tissues from the mice were prepared, fixed 
in 4% paraformaldehyde solution in PBS, embedded in paraffin, and sectioned for staining with H&E. His-
topathology were examined based on the severity of  tissues destruction, eosinophil infiltration, and lym-
phocytic infiltration (Weak, no tissue destruction and rare eosinophil and lymphocyte infiltration; moder-
ate, no tissue destruction and severe lymphocytes and eosinophil infiltration in dermis; severe, destruction 
of  skin formation and severe lymphocytic and eosinophilic infiltration in dermis and epidermis). For IHC 
with patient samples, collected inflamed skin regions were stained with anti-ETS1 (Santa Cruz Biotechnol-
ogy Inc., sc-350) and appropriate peroxidase-conjugated secondary antibodies (Abcam, catalog ab6721). 
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Stained ETS1 protein was visualized with EnVision FLEX+, Mouse, High pH (Agilent, Dako) according 
to manufacturer protocol. For each case, lymphocytes were counted in three 400× fields with the aid of  
a grid and a mechanical counting device. Numbers of  ETS1+ cells in the same fields were counted and 
expressed as a ratio of  total lymphocytes.
Measurement of  IgG and IgE. Serum IgG and IgE level was measured by ELISA kit (BD Biosciences) 
following manufacture protocol. Three wells were prepared for each antigen and serum, and the concen-
tration and OD value indicated the average of  each well and serum. Mean absorbance of  an antigen wells 
minus mean absorbance of  a nonantigen well was used as the OD value of  the antigen.
Isolation of  CD4+ T cells and total ear residual cells. Naive CD4+ T cells were purified from the dLNs of  
the mice by using a CD4+ negative selection method (Stem Cell Technologies) or flow cytometry–based 
cell sorting for CD4+CD25–CD44loCD62Lhi cells. Ears were removed from the mice, cut into 3 pieces, and 
washed with PBS. The ear segments were gently stirred in flasks with solution (PBS containing 25 ml 10 
mM EDTA [Tech&Innovation], 3% FBS [HyClone Laboratories], 20 mM HEPES [Tech&Innovation], 
and 1 mM sodium pyruvate [Welgene Inc.]) for 20 minutes at 37°C and then washed 3 times with PBS. 
The ear pieces were minced and incubated 5 ml RPMI 1640 containing 1 mg/ml collagenase type V (Mil-
liporeSigma) for 45 minutes in 37°C incubator (Hanyang Scientific Equiment Co., Ltd) on the magnetic 
stirrer . Finally, the soup containing total ear cells was centrifuged and washed with ice-cold PBS and cul-
tured in T cell media.
In vitro Th cell differentiation. Naive CD4+ T cells were stimulated with plate-bound anti-CD3 (1 μg/ml) 
(BioXcell, clone 145-2C11) and anti-CD28 (2 μg/ml) (BioXcell, clone 37.51) in medium supplemented as 
follows: for Th1 differentiation, IL-12 (10 ng/ml) and anti–IL-4 (10 μg/ml) (BioXcell, clone 11B11); for 
Th2 differentiation, IL-4 (10 ng/ml) and anti–IFN-γ (10 μg/ml); for conventional Th17 differentiation, 
IL-6 (20 ng/ml), TGF-β1 (2 ng/ml), anti–IFN-γ (10 μg/ml) (BioXcell, clone XMG1.2), and anti–IL-4 
(10 μg/ml); for pathogenic Th17 differentiation, IL-1β (20 ng/ml), IL-6 (20 ng/ml), IL-23 (20 ng/ml), 
anti–IFN-γ (10 μg/ml), and anti–IL-4 (10 μg/ml) (32). All antibodies are purchased from the BioXcell, and 
recombinant cytokines are purchased from the Miltenyi Biotec.
Flow cytometric analysis. To detect tissues infiltrated population, anti–CD4-Alexa488, anti–CD8a-PE, 
and anti–CD19-BV421 (BioLegend; catalogs 100529, 100707, 115549, respectively) were used. For check-
ing T cell differentiation into various Th cells and ex vivo cells, cells were stained with anti–Tbet-Alexa647 
(BD Bioscience, 561267), anti–GATA3-PE, anti–RORγt-APC, anti–AHR-Alexa488 (eBioscience; catalogs 
12-9966-42, 17-6981-82, 53-5925-82, respectively), and anti–Aiolos-PE (BioLegend, 653204). To analyze 
intracellular IL-4, IL-13, IL-10, IFN-γ, IL-17A, and IL-22, cells were permeabilized with IC fixation buffer 
(eBioscience), washed and stained with anti–IL4-APC, anti–IL13-PE, anti–IFN-γ eFluor450, anti–IL22-PE 
(eBioscience; catalogs 17-7041-81, 12-7133-81, 48-7311-82, 12-7221-80, respectively), anti–IL10-BV421, 
and anti–IL17A-APC (BioLegend; catalogs 505021, 506916, respectively). Antibodies for anti–Foxp3-PE, 
anti–Ki-67-PerCP-eFluor710 (eBioscience; catalogs 12-5773-82, 46-5698-82, respectively), anti–Helios-Al-
exa488, anti–CD44-APC, anti–CD62L-BV421, anti–IL6Rα-APC (BioLegend; catalogs 137223, 103012, 
104436, 115812, respectively), and anti–gp130-PE (R&D systems, FAB4681P) were used in some experi-
ments. The samples were analyzed using the LSRFortessa flow cytometer, and data were analyzed using 
FlowJo software.
RNA isolation, cDNA synthesis, and quantitative PCR. Total RNA was extracted from cells with TRIzol 
reagent (Molecular Research Center) according to the manufacturer’s protocol. For reverse transcrip-
tion, up to 1 μg total RNA was used per sample, and cDNA was generated using an oligo (dT) primer 
(Promega) and ImProm-II reverse transcriptase (Promega) in a total volume of  20 μl. The mRNA lev-
el was determined using 1 μl of  diluted cDNA by real-time PCR (Rotor-gene Q, Qiagen) with SYBR 
Green (Takara), using a protocol provided by the manufacturer. Mouse hypoxanthine phosphoribosyl-
transferase (HPRT) primer was used for quantitative PCR (qPCR) to normalize the amount of  cDNA 
used for each condition. The following primers, in-house designed or obtained from other references 
and PrimerBank (https://pga.mgh.harvard.edu/primerbank/) (60), were used in the study. Hprt: for-
ward, 5′-TCAGTCAACGGGGGACATAAA-3′ and reverse, 5′-GGGGCTGTACTGCTTAACCAG-3′ 
(PrimerBank ID 7305155a1); Ets1: forward, 5′-TTTCTGACCCAGATGAGGTGG-3′ and reverse, 
5′-GCATCCGGCTTTACATCCAG-3′; Flg2: forward, 5′-GAGCAAGGATGAGCTAAAGGAAC-3′ and 
reverse, 5′-GCCACGCCTATGCTTCTTTGAC-3′; Cldn1: forward, 5′- ATCGCAATCTTTGTGTCCAC-
CATTG-3′ and reverse, 5′-ATTCTGTTTCCATACCATGCTGTGG-3′ (61); Lor: forward, 5′-CACAT-
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CAGCATCACCTCCTTCC-3′ and reverse, 5′-CCTCCTCCACCAGAGGTCTTTC-3′ (62); S100A8: for-
ward, 5′-CTTCAAGACATCGTTTGAAAGG-3′ and reverse, 5′-ATATTCTGCACAAACTGAGGAC-3′; 
S100A9: forward, 5′-TAGCCTTGAGCAAGAAGATGG-3′ and reverse, 5′-CTGATTGTCCTGGTTTGT-
GTCC-3′; Il6st: forward, 5′-CCGTGTGGTTACATCTACCCT-3′ and reverse, 5′-CGTGGTTCTGTT-
GATGACAGTG-3′ (PrimerBank ID 6754338a1); Il6ra: forward, 5′-CCTGAGACTCAAGCAGAAAT-
GG-3′ and reverse, 5′-AGAAGGAAGGTCGGCTTCAGT-3′ (PrimerBank ID 52693a1); Ikzf3: forward, 
5′-CTGAATGACTACAGCTTGCCC-3′ and reverse, 5′-GCTCCGGCTTCATAATGTTCT-3′ (Prim-
erBank ID 2150044a1); Il2: forward, 5′-TGAGCAGGATGGAGAATTACAGG-3′ and reverse, 5′-GTC-
CAAGTTCATCTTCTAGGCAC-3′ (PrimerBank ID 1504135a1).
Immunoblotting (IB), IP/LC-MS/MS analysis and co-IP. Total cell protein extracts were prepared in RIPA 
buffer and subjected to immunoblotting assay as described previously (63). IB was performed using stan-
dard procedures with anti-Ets1 (Santa Cruz Biotechnology Inc.), anti–phospho-STAT3, anti-STAT3 (Cell 
Signaling Technology), and anti-Actin (Abcam) and was then visualized using ImageQuant LAS 4000 (GE 
Healthcare). Band intensity was quantified using ImageJ software (NIH). For IP/LC-MS/MS analysis, 20 
mg of  cell lysate from stimulated primary CD4+ T cells was immunoprecipitated with 40 μg of  anti-Ets1 
overnight at 4°C, and 100 μl of  protein A magnetic bead (Invitrogen) was added and further incubated for 
2 hours at 4°C. Each immunoprecipitate was washed with cell lysis buffer 3 times, washed with 1× PBS 3 
times. Precipitates were eluted in 8 M Urea for further LC-MS/MS analysis. For co-IP, 1 mg of  cell lysate 
from ex vivo CD4+ T cells was immunoprecipitated with 4 μg of  anti-Ets1 overnight at 4°C. Protein A mag-
netic bead (20 μl) was added and further incubated for 2 hours at 4°C. Each immunoprecipitate was washed 
with cell lysis buffer 3 times, followed by 1× PBS 3 times, separated by SDS-PAGE, and then transferred 
onto a supported nitrocellulose membrane (Bio-Rad). Immunoblotting was performed using standard pro-
cedures with anti-HDAC1 (Abcam) and anti-mSin3A (Santa Cruz Biotechnology Inc.).
ChIP. ChIP assays were performed as described previously (63). In brief, cells were cross-linked with 
formaldehyde at a final concentration 1%, lysed, and sonicated to shear DNA. After IP with anti-H3K27ac 
(Abcam, ab4729) or rabbit IgG (Vector Laboratories, I-1000) at 4°C overnight, Ab/DNA complexes were 
eluted, and cross-linking was reversed by boiling. After reversal of  cross-links, the presence of  selected DNA 
sequences was assessed by real-time PCR using the following primers. Il6st Enh1: forward, 5′-CTCAAAGCT-
CAAGTACTACAGCA-3′ and reverse, 5′-AATACTCCCAGGAGCTCATACAC-3′; Il6st Enh2: forward, 
5′-ACTTAAGATCAGAACTCTGGAGTC-3′ and reverse, 5′-CTCTGAGCATGCAAAGTGTG-3′; Il6st 
Prom: forward, 5′-CGATCTAGTCTAGGAAAGGCGA-3′ and reverse, 5′-CTCATTGGCTCTGGT-
CAGTC-3′. As a loading control, the qPCR was done directly on input DNA purified from chromatin before 
IP. Data are presented as the amount of  DNA recovered relative to the input control. Rpl30 and Mest (Cell 
Signaling Technology, 7015 and 12928) were used as positive and negative control, respectively.
RNA-seq, ChIP-seq, and analysis. dLNs near sites of  inflammation under AD-like skin inflammation 
were excised from LMC and Ets1ΔdLck mice and prepared into single cell suspensions. CD4+ T cells were 
purified by CD4+ negative selection method (Mouse CD4+ T cell negative selection kit; Stem Cell Technol-
ogies). Three replicates of  each group were prepared. RNA were isolated using RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instruction. Libraries were prepared using the TruSeq Stranded mRNA Sam-
ple Preparation Kit (Illumina), and sequencing was done on an Illumina NextSeq 500, 75 paired-end cycles. 
The quality of  the sequenced reads was determined using the FastQC tool, and contaminated adaptor 
sequences were trimmed using the Cutadapt tool. The trimmed sequence reads were aligned to the mouse 
reference genome mm9 using Bowtie2. The abundance of  transcripts was estimated using the Tuxedo 
protocol (Tophat and Cufflinks). Fragments per kilobase of  transcript per million mapped reads (FPKM), 
which is normalized expression level, was generated with Cuffnorm, and differentially expressed genes 
(DEGs) were identified using Cuffdiff. DEGs were defined as the genes that were differentially expressed 
in CD4+ T cells from LMC and Ets1ΔdLck mice, showing less than a FDR-adjusted P value cutoff  of  0.05. 
We further discarded genes showing less than 1.5-fold changes of  up- or downregulated genes between 
conditions. To identify gene sets significantly involved in known pathways, gene set enrichment analysis 
(GSEA) was performed with the identified up- or downregulated genes. RNA-seq data were deposited in 
the NCBI’s Gene Expression Omnibus (GEO GSE122795) (https://www.ncbi.nlm.nih.gov/geo/). Mouse 
Ets1 ChIP-seq from T conventional cells and CD4+Foxp3– T cells were downloaded from GEO with the 
following accession numbers, respectively: NCBI SRA accession number SRX2680314 and GEO data-
base accession number GSM999187. Reads from the ChIP-seq data were aligned to the mouse reference 
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genome mm9 using Bowtie2. Genome-wide Ets1 binding sites were identified using HOMER (64) with 
default parameters. Integrative genomics viewer (IGV) (65) was used to examine loci of  interest associated 
with Ets1 binding.
Mixed BM chimera generation. BM  cells from CD45.2 LMC or CD45.2 Ets1ΔdLck mice were mixed with 
BM cells from congenic CD45.1 WT mice at a 1:1 ratio. These BM mixtures (5 × 106) were injected into 
irradiated Rag1−/− hosts (300 cGy). At 6–8 weeks after BM cell transfer, cells from LN and spleen were 
analyzed by flow cytometry.
Statistics. Statistical analyses were performed using Prism (GraphPad Software) by the unpaired, 
2-tailed Student’s t test, 1-way ANOVA, or 2-way ANOVA. P values below 0.05 were considered significant 
in the following manner: *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.0005; ****P ≤ 0.0001.
Study approval. All human studies were reviewed and approved by the Cheonnam National University 
Hospital and IRB (IRB approval number CNUH-2014-053). Written informed consent was obtained from 
all subjects. All animal experiments were in accordance with protocols approved by the POSTECH IACUC.
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